Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has The Patient Derived Xenograft (PDX) Models Market Size Shifted, And What Is the Outlook Through 2034?

In the past few years, the patient derived xenograft (PDX) models market has seen a swift growth. The market, which stood at $0.4 billion in 2024, is projected to expand to $0.47 billion in 2025, marking a compound annual growth rate (CAGR) of 16.4%. This surge in the historic timeframe is due to factors such as investments in research & development, regulatory backing, partnerships and collaborations, an increase in the number of contract research organizations (CROs), and a rise in cancer cases.

How Much Will the Patient Derived Xenograft (PDX) Models Market Be Worth in 2029?

In the coming years, a significant expansion is projected in the patient-derived xenograft (PDX) models market, with it escalating to $0.85 billion by 2029, registering a compound annual growth rate (CAGR) of 16.0%. The rise through the forecast period is linked to the increasing demand for tailored medical solutions, the surge in request for humanized PDX models, the growing prevalence of cancer, an emphasis on precision oncology, and proliferating R&D funding for cancer exploration. Key trends in this projection period include advancements in technology, an increased need for humanized PDX models, joint research enterprises, escalating investments in cancer inquiries, and an amplified focus on immuno-oncology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17226&type=smp

Which is the Largest Company in the Patient Derived Xenograft (PDX) Models Market?

Major companies operating in the patient derived xenograft (PDX) models market are Laboratory Corporation of America Holdings, WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., The Jackson Laboratory, Inotiv Inc, Biocytogen Pharmaceuticals Co. Ltd., Taconic Biosciences Inc, BioDuro-Sundia Inc, Horizon Discovery Ltd., Crown Bioscience Inc., Champions Oncology Inc., Oncodesign Services S.A, Genesis Biotechnology Group LLC., Creative Animodel, Abnova Corp., Certis Oncology Solutions Inc., Xentech, Aragen Bioscience Inc., EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH., Urosphere, Hera BioLabs, InnoSer, Pharmatest Services Ltd., IVRS AB, Altogen Inc

What Are the Main Market Drivers in the Patient Derived Xenograft (PDX) Models Industry?

The growth of the patient-derived xenograft (PDX) models market is predicted to be fueled by the rising demand for personalized medicine. This type of medical care is tailored specifically to the individual patient, taking into account factors like genetics, environment, and lifestyle. The push for personalized medicine is a result of advancements in genomic research, which allows for treatments to be specifically adjusted based on a person’s genetic profile, leading to more effective and targeted healthcare results. PDX models are instrumental in supporting personalized medicine as they allow for individual patient tumors to be tested to predict treatment response and adjust therapies accordingly. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based non-profit organization, noted that the FDA approved 16 new personalized treatments for rare diseases in 2023, marking a significant rise from just six approvals in 2022. Therefore, the growth of the patient-derived xenograft (PDX) models market is being propelled by the increasing demand for personalized medicine.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=17226&type=smp

How Is the Patient Derived Xenograft (PDX) Models Market Segments Structured?

The patient derived xenograft (PDX) models market covered in this report is segmented –

1) By Type: Mice Models, Rat Models

2) By Technique: Heterotopic Implantation, Orthotropic Implantation

3) By Tumor Type: Gastrointestinal Tumor Models, Lung Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, Urological Tumor Models, Other Tumor Models

4) By Application: Preclinical Drug Development, Precision Medicine, Co-Clinical Trials, Basic Cancer Research

5) By End-User: Academic And Research Organizations, Contract Research Organizations, Pharmaceutical And Biotechnological Companies, Other End-Users

Subsegments:

1) By Mice Models: Immunodeficient Mice Models (Nude Mice, SCID Mice), Humanized Mice Models, Genetically Modified Mice Models

2) By Rat Models: Immunodeficient Rat Models, Humanized Rat Models, Genetically Modified Rat Models

What Strategic Trends Are Transforming the Patient Derived Xenograft (PDX) Models Market?

Leading companies in the patient-derived xenograft (PDX) models market are introducing innovative models equipped with in vivo bioluminescence imaging for real-time tracking of tumor development. This technology enhances the PDX models’ capacity for non-invasive, real-time observation of tumor metastasis and therapy responses, thereby improving the efficacy of preclinical drug development research. In March 2024, for example, India’s Contract Research Organization (CRO), InVitro Research Solutions Private Limited, developed a novel orthotopic model of human glioblastoma in NSG-SGM3 mice using PDX and in vivo bioluminescence imaging. This model’s aim is to enable individualized treatment of glioblastoma, the most prevalent and invasive form of brain cancer. These models are instrumental in learning more about glioblastoma biology and testing new targeted treatments and immunotherapies to enhance results.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/patient-derived-xenograft-pdx-models-global-market-report

Which Global Regions Offer the Highest Growth in the Patient Derived Xenograft (PDX) Models Market?

North America was the largest region in the patient derived xenograft (PDX) models market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient derived xenograft (PDX) models market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17226

This Report Delivers Insight On:

1. How big is the patient derived xenograft (pdx) models market, and how is it changing globally?

2. Who are the major companies in the patient derived xenograft (pdx) models market, and how are they performing?

3. What are the key opportunities and risks in the patient derived xenograft (pdx) models market right now?

4. Which products or customer segments are growing the most in the patient derived xenograft (pdx) models market?

5. What factors are helping or slowing down the growth of the patient derived xenograft (pdx) models market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model